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RANKL/RANK promotes the migration 
of gastric cancer cells by interacting with EGFR
Xing Wan1, Yongxi Song2, Honghong Fang3, Ling Xu1, Xiaofang Che1, Shuo Wang1, Xiaomeng Zhang1, 
Lingyun Zhang1, Ce Li1, Yibo Fan1, Kezuo Hou1, Zhi Li1, Xueqing Wang4, Yunpeng Liu1* and Xiujuan Qu1*
Abstract 
Background: The incidence and mortality rates of gastric cancer (GC) rank in top five among all malignant tumors. 
Chemokines and their receptor-signaling pathways reportedly play key roles in the metastasis of malignant tumor 
cells. Receptor activator of nuclear factor κB ligand (RANKL) is a member of the tumor necrosis factor family, with 
strong chemokine-like effects. Some studies have pointed out that the RANKL/RANK pathway is vital for the metasta-
sis of cancer cells, but the specific mechanisms in GC remain poorly understood.
Results: This study reports original findings in cell culture models and in patients with GC. Flow cytometry and 
western blotting analyses showed that RANK was expressed in BGC-823 and SGC-7901 cells in particular. Chemotaxis 
experiments and wound healing assay suggested that RANKL spurred the migration of GC cells. This effect was offset 
by osteoprotegerin (OPG), a decoy receptor for RANKL. RANKL contributed to the activation of human epidermal 
growth factor receptor (HER) family pathways. The lipid raft core protein, caveolin 1 (Cav-1), interacted with both RANK 
and human epidermal growth factor receptor-1(EGFR). Knockdown of Cav-1 blocked the activation of EGFR and cell 
migration induced by RANKL. Moreover, RANK-positive GC patients who displayed higher levels of EGFR expression 
had poor overall survival.
Conclusions: In summary, we confirmed that with the promotion of RANKL, RANK and EGFR can form complexes 
with the lipid raft core protein Cav-1, which together promote GC cell migration. The formation of the RANK-Cav-
1-EGFR complex provides a novel mechanism for the metastasis of GC. These observations warrant confirmation in 
independent studies, in vitro and in vivo. They also inform future drug target discovery research and innovation in the 
treatment of GC progression.
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Background
A recent study reported that the incidence and mortality 
rates of GC rank second among all malignant tumors [1]. 
The majority of patients miss the opportunity to be cured 
by surgery. Less than 10% of them can live for more than 
five years and the median survival time is less than 1 year 
[2]. One of the major causes of the low survival rate is 
local infiltration and abdominal implant transfer due to 
GC cell migration.
In recent years, chemokines and their receptor-signal-
ing pathways have been reported to have major roles in 
the metastasis of cancer cells [3]. RANKL is the ligand 
of RANK, with a strong chemokine-like effect [4]. The 
presence of RANKL/RANK pathway has been con-
firmed in malignant tumors of the respiratory, endocrine, 
reproductive, and lymphatic systems [5–7]. The RANK/
RANKL pathway has also been demonstrated to be an 
important regulator of mammary stem cells and mam-
mary gland development [8]. In addition, it is vital for the 
initiation, progression, and metastasis of breast cancer 
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[9, 10]. Recently, GC sufferers with high levels of RANKL 
expression have been confirmed to have shorter overall 
survival [11].
The biological function, mechanism, and significance 
of the epidermal growth factor receptor family have 
been extensively reported. EGFR and HER2 are gener-
ally considered to be markers of poor prognosis in GC 
sufferers [12, 13]. Studies have shown that RANK can 
interact with EGFR to regulate osteoclast differentiation 
and survival [14]. Furthermore, the interaction between 
EGFR and RANK has been corroborated in vitro and in 
animal models of metastasis. In addition, the RANK/
RANKL axis also has a crucial impact on the occurrence 
of ErbB2-positive breast cancer [15]. Rodent experi-
ments have shown that RANK can lead to breast cancer 
progression and can induce early-stage tumor metastasis 
in HER2-positive breast cancer models, by direct ligand 
stimulation [16, 17]. According to our present research, 
RANKL not only stimulated the migration of GC cells, 
but also promoted EGFR activation, which could be 
blocked by Cav-1 knockdown. The discovery of this 
RANK-Cav-1-EGFR complex revealed a novel mecha-
nism for the metastasis of GC.
Results
RANKL induced the migration of GC cells via RANK 
and EGFR
We first verified the RANK expression in various GC 
cells by western blot (Fig. 1a). After comparison, RANK 
protein expression levels were highest in BGC-823 and 
SGC-7901 GC cells. We then tested whether RANK was 
expressed on the surface of these GC cells. Flow cytom-
etry results showed RANK expression on the surface 
of BGC-823 and SGC-7901 GC cells (Fig.  1b). Tran-
swell experiments were then used to determine whether 
RANKL could promote GC cell migration. The results 
indicated that RANKL (1.0 μg/mL) promoted the migra-
tion of GC cells, compared to untreated cells. After the 
addition of its inhibitor, OPG (10  μg/mL), RANKL-
induced GC cell migration was significantly attenuated 
(Fig. 1c). After being treated with the same reagent and 
concentration as transwell, the wound healing experi-
ments further confirm the phenomenon above (Fig. 1d). 
These results suggested that RANKL stimulated the 
migration of GC cells through RANK.
To investigate whether RANKL had an effect on the 
HER family, we treated both GC cells with RANKL for 
the indicated times and observed the level of phospho-
rylated EGFR. EGFR phosphorylation was obviously 
up-regulated at 5 min in BGC-823 and 15 min in SGC-
7901. Other members of the HER family also showed 
transient or sustained phosphorylation (Fig. 2a). Moreo-
ver, the downstream molecular changes induced by the 
RANKL-mediated activation of EGFR were offset by 
transfection of siEGFR (Fig.  2b). Silencing EGFR also 
partially reversed RANKL-induced GC cell migration 
(Fig.  2c, d). This indicated that RANKL promoted the 
migration of GC cells through EGFR and its downstream 
signaling pathway.
The activation of EGFR by RANKL depended on Cav‑1
Numerous membrane receptors interact with each other 
on the lipid raft platform. To determine the mechanism 
whereby RANKL regulates EGFR, we examined Cav-1, a 
key protein of lipid rafts. The results showed that phos-
phorylated Cav-1 was activated by RANKL in SGC-7901 
cells after 45 min of treatment and in BGC-823 cells after 
15 min of treatment (Fig. 3a). Silencing of the Cav-1 gene 
inhibited RANKL-induced EGFR activation (Fig.  3b). 
This result indicated that RANKL might induce GC cell 
migration by Cav-1-mediated EGFR activation.
RANKL promoted GC cell migration through the formation 
of a RANK‑Cav‑1‑EGFR complex
Since RANKL activated EGFR and Cav-1 and Cav-1 
regulated EGFR activation, we explored the interaction 
between these proteins. Our results showed that Cav-1 
naturally bound to RANK and EGFR. When treated 
with RANKL, the interaction of Cav-1, RANK, and 
EGFR increased after 5  min in BGC-823 cells and after 
15 min in SGC-7901 cells (Fig. 4a). Knockdown of Cav-1 
inhibited the RANK-Cav-1-EGFR complex assembling 
(Fig.  4b). Taken together, these findings indicated that 
RANKL induced GC cell migration through the forma-
tion of a RANK-Cav-1-EGFR complex.
High levels of EGFR expression were associated with worse 
overall survival in RANK‑positive GC sufferers
To clarify the impact of RANK and EGFR on disease 
prognosis, we collected 68 primary GC specimens and 
used immunohistochemistry to assess EGFR and RANK 
expression. Immuno-staining confirmed high levels of 
EGFR expression in 19 patients (27.9%) and high levels 
of RANK expression in 28 patients (41.2%, Fig.  5a). We 
grouped RANK-positive patients based on their level of 
EGFR expression.
Table  1 shows the correlation between EGFR expres-
sion and clinic-pathological features in RANK high 
expression group. The univariate analysis showed that 
gender and age were not associated with EGFR expres-
sion. There existed a positive correlation between EGFR 
expression and TNM staging and N staging. We get 
the conclusion that the prognosis was significantly bet-
ter in those with low EGFR expression sufferers than 
in those with high EGFR expression sufferers (Fig.  5b). 
This schematic diagram shows our research content very 
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intuitively: After being stimulated by RANKL, the trans-
membrane proteins EGFR and RANK form a complex 
with Cav-1 on the lipid raft platform, which further acti-
vates downstream signaling pathways and ultimately pro-
motes gastric cancer migration (Fig. 5c).
Discussion
Numerous evidence supports RANK’s important 
function in the development and progression of can-
cer. RANKL stimulates RANK and has effects on the 
migration and invasion of cancer cells. Furthermore, 
RANKL/RANK function as predictors of tumorigenesis 
and prognosis in many solid tumors, including breast 
cancer and GC [18–20]. RANKL and its receptor, RANK, 
can be modulated by EGFR signaling [21]. However, the 
precise molecular mechanisms by which these two path-
ways interact with each other to affect cancer cell migra-
tion remain unclear.
In the present study, flow cytometry and immunob-
lotting experiments demonstrated that RANK exists in 
Fig. 1 RANKL promotes gastric cancer cell migration through RANK. a Western blot showed that RANK protein was expressed in various gastric 
cancer cells. b The results of flow cytometry showed that there were two peaks of blue and red in gastric cancer cells, indicating that there was 
a high expression of RANK on the surface of gastric cancer cells. c SGC-7901 and BGC-823 cells were treated with RANKL (1 μg/ml) for 24 h. The 
transwell assay results showed that the number of cell migration increased significantly. When OPG (10 μg/ml) was added at the same time, the 
effect of RANKL was cancelled out. d The wound healing assay (magnification, × 100) also confirmed that RANKL can promote gastric cancer 
migration. Data are mean ± SD in three independent experiment. (**p < 0.01)
Page 4 of 9Wan et al. Clin Trans Med             (2020) 9:3 
Fig. 2 RANKL promotes migration of gastric cancer cells by activating EGFR pathway. a After treatment with RANKL at different time points, the HER 
family members showed persistent or transient phosphorylation activation by western blot. b RANKL can up-regulate the levels of P-EGFR, P-AKT 
and P-ERK. However, this effect can be counteracted by transfection of siEGFR. c, d The transwell assay and wound healing assay results showed 
that the RANKL can up-regulate the number of cell migration increased significantly. Same as above, this effect can be counteracted by transfection 
of siEGFR. Data are mean ± SD in three independent experiment. (**p < 0.01)
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all five GC cell lines, with the highest levels observed in 
SGC-7901 and BGC-823 cells. Consistent with previ-
ous findings, RANK was located on the cell membrane. 
Furthermore, we examined the effect of RANKL on cell 
migration and verified that RANKL promoted the invad-
ing ability of GC cells. Meanwhile, the stimulation of cell 
migration by RANKL could be inhibited by EGFR siRNA. 
More importantly, by activating the EGFR signaling path-
way, RANKL notably activated p-EGFR and the expres-
sion of its downstream protein, MAPK. Our data not 
only showed that RANK promoted tumor cell invasion 
through RANKL, but also suggested that there was cross-
talk between the RANK/RANKL pathway and the EGFR 
signaling pathway.
Another important result in this study was that 
RANKL facilitated the phosphorylation of Cav-1, a key 
component of lipid rafts, which regulate signal trans-
duction at the cell surface [22]. To further explore the 
molecular mechanisms of the interaction between 
RANKL and EGFR in the regulation of GC invasion and 
progression, we silenced Cav-1 protein function using a 
Cav-1 siRNA. The results of these experiments demon-
strated that EGFR activity was regulated by RANKL, in 
a Cav-1-dependent manner. In particular, co-immuno-
precipitation experiments revealed that Cav-1 naturally 
bound with RANK and EGFR. Based on the present find-
ings, we conclude that Cav-1 may make a major contri-
bution to the relationship between RANKL/RANK and 
the EGFR pathway, which are involved in regulating the 
migration of GC cells. These data also provide new ideas 
for explaining and avoiding resistance to EGFR tyrosine 
kinase inhibitors.
While our study suggested new evidence regarding 
the mechanisms of GC progression, several limitations 
should be noted. The clinical study sample size was lim-
ited and therefore, future studies with larger sample 
sizes and in independent populations are required to 
confirm the findings presented here. To further confirm 
that Cav-1 directly or indirectly interacts with RANK or 
EGFR and to identify the functional domain of the bind-
ing site, genetic variants of RANK, EGFR, and Cav-1 
should be employed. In addition, GST pull-down experi-
ments could be used to advance this emerging body of 
knowledge on GC cell migration and metastasis.
Conclusions
The formation of RANK-Cav-1-EGFR complex pro-
vides a novel mechanism for the metastasis of GC. These 
observations warrant further replication in independent 
studies in vitro and in vivo. They also inform future drug 
target discovery,immunity therapy and diagnostics inno-
vation for GC progression in particular [23].
Materials and methods
Clinical study, participants, and research ethics
Samples of GC tissue were gathered from 68 suffer-
ers who received Radical surgery at the First Hospital of 
China Medical University (Shenyang, China) from March 
2006 to October 2011. No one had ever received any 
form of anti-tumor treatment. Clinical and pathologi-
cal features were evaluated following medical charts and 
pathological records. The Ethical Committee of the First 
Hospital of China Medical University approved the study.
Reagents
RANKL and OPG were obtained from CytoLab/Pepro-
Tech Asia (Rocky Hill, NJ, USA). The Cav-1 siRNA was 
obtained from Shanghai GenePharma Co. Ltd (Shanghai, 
China). The EGFR siRNA and protein agarose beads were 
purchased from Cell Signaling Technology, Inc. (Dan-
vers, MA, USA). Lipofectamine 2000 was purchased from 
Invitrogen (Carlsbad, CA, USA).
Fig. 3 The activation of EGFR by RANKL depends on the existence of 
Cav-1. a The gastric cancer cells were treated with RANKL (1 μg/ml) 
for the indicated times by Western blot, the level of p-Cav-1 increased 
significantly, BGC-823 for 15 min and SGC-7901 for 45 min. b While 
we knocked down of Cav-1 gene by using Cav-1 siRNAs for 72 h, 
Cav-1 and P-Cav-1 decreased significantly, P-EGFR also decreased 
significantly
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Fig. 4 RANKL promoted the formation of a RANK-Cav-1-EGFR complex. a The SGC-7901 and BGC-823 cells were treated with RANKL for the 
indicated times. Whole cell lysates were immune-precipitated with anti-Cav-1 antibody. The interaction of CAV-1 with RANK and EGFR was 
significantly enhanced providing by Western blot. b While silencing Cav-1 gene by using Cav-1 siRNAs for 72 h, and then treated with RANKL for 
indicated time. The formation ability of Cav-1-RANK-EGFR complex decreased significantly. Input represents cell lysates that were not subjected to 
immune-precipitation and IgG as an IP-control
Page 7 of 9Wan et al. Clin Trans Med             (2020) 9:3 
Cell culture
Five GC cells were purchased from the Cell Bank of the 
Chinese Academy of Sciences (Shanghai, China). The 
specific methods refer to our previous article [24].
Flow cytometry
BGC-823 and SGC-7901 cells were sowed at 2.5 × 105 
cells/well in six-well plates. RANK expression was 
detected by flow cytometry according to a previously 
described method [25].
Western blotting
Western blotting was performed as previously described 
[25, 26].
Immunoprecipitation assay
Antibodies against EGFR and Cav-1, protein A-agarose 
beads, and cell lysates were incubated for 6  h at room 
temperature. The resulting complex was washed four 
times with lysis buffer. The technical details of this proce-
dure are described in our previous publication [27].
Fig. 5 The relationship between the expression of EGFR and RANK and prognosis. a The cases of simultaneous negative and positive expression of 
EGFR and RANK. b The patients with double positive EGFR and RANK had the worst prognosis. c Schematic diagram of RANKL-mediated complex 
formation leading to enhanced migration of GC cells
Table 1 RANK positive expression and clinicalpathological 
characteristics of GC
Characteristics Cases EGFR
Low (%)  High (%)  p value
Sex
Male 15 (53.6) 9 (32.1) 0.495
Female 3 (10.7) 1 (3.6)
Age (years)
≤ 60 11 (39.3) 5 (17.9) 0.590
> 60 7 (25) 5 (17.9)
pTNM stage
I + II 7 (25) 0 (0) 0.022*
III 11 (39.3) 10 (35.7)
T stage
T1-2 2 (7.1) 0 (0) 0.29
T3-4 16 (57.1) 10 (35.7)
N stage
N0 0 (0) 0 (0) < 0.05*
N1-3 18 (64.3) 10 (35.7)
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Transwell migration assay
For each sample, 200 μl of pretreated cells in serum-free 
RPMI 1640 medium (SGC-7901, 1 × 104 cells/well; BGC-
823, 3 × 104 cells/well; EGFR or Cav-1 gene knocked out) 
was loaded into the upper well. The lower chambers sup-
plemented with or without RANKL. The specific experi-
mental methods refer to our previous article [24].
Wound healing assay
For detailed experimental methods, please refer to our 
previous research [28].
Transfection with small interfering RNA
The cultured cells were transiently transfected by using 
Lipo 2000 at the request of the instructions. The follow-
ing siRNA sequences were used: siCav-1, 5′-AAC CAG 
AAG GGA CAC ACA GUU-3′; EGFR, 5′-CUC CAG AGG 
AUG UUC AAU ATT-3′; and control, 5′-AAT TCT CCG 
AAC GTG TCA CGT-3′. After 48–72 h of transfection, the 
cells were sub-cultured for further experiments.
Immunohistochemical experiments
GC tissues were formalin-fixed, paraffin-embedded, and 
cut into 3 µm sections. The specific details of the immune-
histochemical method have been described in our previous 
report [27]. Briefly, the following antibodies were used for 
immune-histochemical staining: an anti-RANK antibody 
from R&D Systems (Minneapolis, MN, USA) and an anti-
EGFR antibody from Santa Cruz Biotechnology, Inc. (Dal-
las, TX, USA). Two independent pathologists observed 
and evaluated the stained tissue sections by microscopy 
( ×  20 and  ×  40 magnification). Five fields were randomly 
selected from each section and scored based on the per-
centage of positive cells and the staining intensity of the 
cells. Sections with 0–10, 10–25, 26–50, 51–75, or > 76% 
of positively stained cells were recorded as 0, 1, 2, 3, and 4, 
respectively. Scores > 2 were defined as high expression lev-
els and scores of 0–2 were defined as low expression levels.
Statistical analysis
All experiments were performed on at least three inde-
pendent occasions. Data were summarized and are 
showed as the mean ± SD. Statistical comparisons were 
performed using a Student’s t-test, with p < 0.05 considered 
statistically significant. Statistical analysis was performed 
using SPSS 24.0 software (SPSS, Inc., Chicago, IL, USA).
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